Search results for "gastric"

showing 10 items of 536 documents

Is Routine Preoperative Upper Endoscopy in Gastric Banding Patients Really Necessary?

2006

Background: Preoperative evaluation for bariatric surgery is complex. Our investigation focused on the necessity for upper gastrointestinal (GI) endoscopy as a routine procedure before performing gastric banding. Methods: A consecutive series of 145 patients underwent laparoscopic adjustable gastric banding (LAGB). Gastroscopy was performed routinely before LAGB. All patients were interviewed before gastroscopy regarding gastroesophageal symptoms. Gastroscopic findings and the results of the interview were blinded and set in comparison. Furthermore, we analyzed whether upper GI symptoms, BMI, age or gender were predictive parameters for pathological findings on gastroscopy. Small hiatal her…

AdultMalemedicine.medical_specialtyGastroplastyGastric bandingEndocrinology Diabetes and MetabolismGastroenterologyHiatal herniaInternal medicinePreoperative CaremedicineHumansMedical historyEndoscopy Digestive SystemPathologicalNutrition and Dieteticsmedicine.diagnostic_testDiagnostic Tests Routinebusiness.industryMiddle Agedmedicine.diseasedigestive system diseasesObesity MorbidEndoscopySurgeryGastric PolypFemaleSurgeryAbnormalitybusinessEsophagitisObesity Surgery
researchProduct

Laparoscopic gastric banding as a universal method for the treatment of patients with morbid obesity.

2004

Introduction: This study analyzed the influence of potentially negative predictors such as sweet-eating behavior, super-obesity, social and psychological status, family and education situation, intake of sedative drugs, and the distance between hospital and home on the outcome of laparoscopic adjustable gastric banding (LAGB). Methods: 77 women and 29 men with mean age 40.6 years (28-47) underwent LAGB. Preoperative mean body weight was 146 kg (99-179), and mean BMI was 48.1 kg/m 2 (36.4-73.5). The influence of the above-mentioned potentially negative predictors on weight loss was the primary end point. Results: Mean follow-up was 44.6 ′ 19.7 months. Follow-up was possible in all but 6 pati…

AdultMalemedicine.medical_specialtyGastroplastyGastric bandingmedicine.drug_classEndocrinology Diabetes and MetabolismGastric bypassMorbid obesityWeight lossmedicineClinical endpointHumansUnivariate analysisNutrition and Dieteticsbusiness.industryPatient SelectionMiddle AgedSurgeryObesity MorbidTreatment OutcomeSedativeSurgeryFemaleLaparoscopymedicine.symptombusinessLaparoscopic adjustable gastric bandingObesity surgery
researchProduct

Pepsinogen testing for evaluation of the success of Helicobacter pylori eradication at 4 weeks after completion of therapy.

2014

Background and objective: Pepsinogen levels in plasma are increased by inflammation in the gastric mucosa, including inflammation resulting from Helicobacter pylori infection. A decrease in pepsinogen II level has been suggested as a reliable marker to confirm the successful eradication of infection. The aim of our study was to evaluate the potential role of pepsinogens I and II, gastrin-17 and H. pylori antibodies in confirming successful eradication. Material and methods: Altogether 42 patients (25 women, 17 men), mean age 45 years (range 23–74), were enrolled. Pepsinogens I and II, gastrin-17 and H. pylori IgG antibodies were measured in plasma samples using an ELISA test (Biohit, Oyj., …

AdultMalemedicine.medical_specialtyHelicobacter pylori infectionEfficacyGastrin-17macromolecular substancesPepsinogenGastroenterologydigestive systemHelicobacter InfectionsYoung AdultAtrophyPepsinInternal medicinePepsinogen AGastrinsmedicineGastric mucosaPepsinogen CHumansEradicationAgedMedicine(all)lcsh:R5-920biologyPlasma samplesHelicobacter pyloribusiness.industryHelicobacter pyloriMiddle Agedbiology.organism_classificationmedicine.diseaseAntibodies Bacterialdigestive system diseasesmedicine.anatomical_structureTreatment OutcomeGastric MucosaAutomotive Engineeringbiology.proteinPepsinogen IIPepsinogen; Gastrin-17; Eradication; <em>Helicobacter pylori</em>; EfficacyFemaleAntibodybusinesslcsh:Medicine (General)<em>Helicobacter pylori</em>BiomarkersMedicina (Kaunas, Lithuania)
researchProduct

Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis

2019

Abstract Background Few patients affected by gastric cancer peritoneal metastasis (GCPM) are offered locoregional treatment, despite several proof-of-efficacy trials. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has emerged in recent years as a promising tool to control peritoneal carcinomatosis. The combination of PIPAC with systemic chemotherapy may offer a greater clinical benefit than standard treatment alone. Methods A single-center cohort of 28 consecutive patients affected by GCPM was scheduled for bidirectional treatment, comprising PIPAC and systemic chemotherapy, from September 2017 to September 2019. Data recorded included safety, efficacy and survival outcomes. Ascit…

AdultMalemedicine.medical_specialtyIntraoperative Complicationmedicine.medical_treatmentPopulation03 medical and health sciences0302 clinical medicineStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicinePressureHumansProspective StudieseducationPeritoneal NeoplasmsAgedRetrospective StudiesAerosolseducation.field_of_studyChemotherapyPressurized intraperitoneal aerosol chemotherapy (PIPAC)business.industryStandard treatmentCommon Terminology Criteria for Adverse EventsMiddle AgedPrognosisSurgerySurvival RateOncologyDoxorubicin030220 oncology & carcinogenesisCohortConventional PCIPeritoneal metastasisPeritoneal Cancer Index030211 gastroenterology & hepatologySurgeryFemaleCisplatinbusinessGastric cancerFollow-Up Studies
researchProduct

Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocar…

1994

Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i.v. on days 1, 29; mitomycin C 10 mg/m2 i.v. on day 1. This cycle was repeated every 8 weeks. Out of a total of 34 evaluable patients, 2 (5.8%) had a complete response and 7 (20.6%) had a partial response with an overall median duration of 40 weeks (range 20-128). The median survival of responding patients was not reached after a mean follow-up of 76 weeks, while that of patients with no change and progressive disease was reached at 36 and 13 weeks respectively. Treatment was generally well tolerated with h…

AdultMalemedicine.medical_specialtyMitomycinmedicine.medical_treatmentAdenocarcinomaGastric Adenocarcinoma Chemotherapy Epidoxorubicin Mitomicin CGastroenterologyStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedEpirubicinAged 80 and overPharmacologyChemotherapybusiness.industryStomachPalliative CareMitomycin CCombination chemotherapyMiddle Agedmedicine.diseaseConfidence intervalSurgeryInfectious Diseasesmedicine.anatomical_structureOncologyFluorouracilAdenocarcinomaFemaleFluorouracilbusinessProgressive diseasemedicine.drug
researchProduct

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagoga…

2009

The combination of irinotecan with 5-fluorouracil demonstrates efficacy with tolerable safety in the first-line treatment of metastatic gastroesophageal cancer (mGC). This randomized phase II trial compared for the first time capecitabine with irinotecan or cisplatin in this setting.Patients were randomly assigned to receive 3-week cycles of capecitabine 1000 mg/m(2), twice daily for 14 days, with on day 1 either irinotecan 250 mg/m(2) (XI) or cisplatin 80 mg/m(2) (XP). The primary end point was overall response rate (ORR) and secondary end points included progression-free survival (PFS), overall survival (OS) and safety.Of 118 patients recruited, 112 were eligible for safety analysis and 1…

AdultMalemedicine.medical_specialtyPhases of clinical researchKaplan-Meier EstimateAdenocarcinomaIrinotecanDeoxycytidineGastroenterologyCapecitabineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalStomach cancerCapecitabineAgedbusiness.industryCombination chemotherapyHematologyMiddle Agedmedicine.diseaseSurgeryIrinotecanRegimenOncologyFluorouracilCamptothecinFemaleEsophagogastric JunctionFluorouracilCisplatinbusinessmedicine.drugAnnals of Oncology
researchProduct

Gastric emptying of indigestible tablets in relation to composition and time of ingestion of meals studied by metal detector.

1991

Enteric-coated tablets leave the stomach mainly during the interdigestive phase. Composition as well as time of ingestion of meals may influence their gastric emptying considerably. In 12 normal volunteers gastric emptying of a plastic tablet with a metal core was followed by a metal detector in relation to different compositions and various times of ingestion of meals. With an empty stomach and after ingestion of 250 ml water, the mean time for gastric emptying of the tablet was 38 +/- 11 min (mean +/- SEM) and 38 +/- 8 min. Two hundred fifty milliliters of milk (652 kJ) and a formula diet (1000 kJ) delayed gastric emptying time to 128 +/- 14 and 152 +/- 6 min, respectively (P less than 0.…

AdultMalemedicine.medical_specialtyPhysiologyGastroenterologyEatingInternal medicinemedicineIngestionHumansEnteric coatedEating habitsMorningGastric emptyingbusiness.industryStomachdigestive oral and skin physiologyGastroenterologyMiddle AgedBioavailabilitymedicine.anatomical_structureGastric EmptyingFoodMetalsComposition (visual arts)FemaleTablets Enteric-CoatedbusinessDigestive diseases and sciences
researchProduct

Pepsinogen Test for the Evaluation of Precancerous Changes in Gastric Mucosa: a Population-Based Study

2018

Aims: The aim of the study was to evaluate the rationale of blood pepsinogen (PG) testing in population based screening settings.Methods: Participants from a cross-sectional population-based study of cardiovascular risk factors in Latvia were invited to participate in the current study. Pepsinogen I and II were measured in blood samples taken during the initial study and at follow-up; upper gastrointestinal endoscopy was performed. There were three groups of patients: with moderately decreased (PG I&lt; 70 ng/ml and PG I/PG II ratio &lt; 3), with strongly decreased (PG I&lt; 30 ng/ml and PG I/PG II ratio &lt; 2), and with normal PG level. Biopsy with H. pylori detection was performed (updat…

AdultMalemedicine.medical_specialtyPopulationGastroenterologyEndoscopy GastrointestinalHelicobacter Infections03 medical and health sciences0302 clinical medicinePepsinStomach NeoplasmsPepsinogen AInternal medicine0502 economics and businessBiopsyPepsinogen CGastric mucosamedicineHumansMass ScreeningeducationMass screeningAgededucation.field_of_studyHelicobacter pyloribiologymedicine.diagnostic_testbusiness.industryStomach05 social sciencesGastroenterologyCancerMiddle AgedHelicobacter pyloribiology.organism_classificationmedicine.diseasemedicine.anatomical_structureDysplasiaElder Nutritional Physiological PhenomenaGastritisbiology.proteinFemale050211 marketing030211 gastroenterology & hepatologyAtrophybusinessJournal of Gastrointestinal and Liver Diseases
researchProduct

Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion.

2021

Non-cirrhotic portal vein thrombosis (PVT) in patients with antiphospholipid syndrome (APS) is a rare complication, and the management has to be determined individually based on the extent and severity of the presentation. We report on a 37-year-old male patient with non-cirrhotic chronic PVT related to a severe thrombophilia, comprising APS, antithrombin-, factor V- and factor X-deficiency. Three years after the initial diagnosis of non-cirrhotic PVT, the patient presented with severe hemorrhagic shock related to acute bleeding from esophageal varices, requiring an emergency transjugular intrahepatic portosystemic stent shunt (TIPSS). TIPSS was revised after a recurrent bleeding episode du…

AdultMalemedicine.medical_specialtyPortal venous pressuremedicine.medical_treatment030204 cardiovascular system & hematologyThrombophiliaEsophageal and Gastric Varices03 medical and health sciences0302 clinical medicineEsophageal varicesHypertension PortalmedicineHumansThrombophiliaEmbolizationPatient Care TeamVenous Thrombosisbusiness.industryPortal VeinGastroenterologymedicine.diseaseThrombosisSurgeryPortal vein thrombosisPortal hypertension030211 gastroenterology & hepatologyStentsPortasystemic Shunt Transjugular IntrahepaticbusinessVaricesGastrointestinal HemorrhageZeitschrift fur Gastroenterologie
researchProduct

Saliva variations in gastro-oesophageal reflux disease.

2007

Abstract Objectives The protective role of saliva in the case of oesophageal exposition to gastric acid has long been studied but some contradictions still remain. The main end-point of this study was to evaluate if a qualitative and quantitative alteration in salivary secretion exists in patients affected by GERD. Methods One hundred and twenty patients (T group) with clinically and endoscopically diagnosed GERD, and 98 healthy subjects (C group) have been evaluated; salivary tests (i.e. basal flow rate, stimulated flow rate, pH, [Na + ] and [K + ]) were performed, socio-demographical variables and oral GERD-related symptoms were taken into account. SPSS 10.5 software was used for statisti…

AdultMalemedicine.medical_specialtySalivaBurning Mouth SyndromeGastroenterologyXerostomiaStatistics NonparametricBasal (phylogenetics)Gastro-Internal medicinemedicineHumansSalivaGeneral DentistryAgedChi-Square Distributionbusiness.industryRefluxCase-control studyMiddle Agedmedicine.diseaseprotective role of salivahumanitiesdigestive system diseasesSurgeryCross-Sectional StudiesCase-Control StudiesGERDGastroesophageal RefluxGastric acidFemalebusinessSecretory RateChi-squared distributionJournal of dentistry
researchProduct